Breaks Categories: News

MondayJul 31, 2017 12:57 pm

NetworkNewsBreaks – China Internet Nationwide Financial Services, Inc. (NASDAQ: CIFS) Prices $20M Initial Public Offering

China Internet Nationwide Financial Services (NASDAQ: CIFS) this morning announced the pricing of its initial public offering of 2,023,146 of its ordinary shares at $10 per unit. The provider of financial advisory services to the underserved small-to-medium-sized enterprises (“SMEs”) market in China said its shares are expected to begin trading on the NASDAQ Global Market on August 8, 2017, under the symbol “CIFS.” FBR Capital Markets & Co. and B. Riley & Co., LLC are acting as joint book-running managers for the offering. The company has granted the underwriters a 45-day option to purchase up to 3,000,000 additional units at…

Continue Reading

MondayJul 31, 2017 12:16 pm

NetworkNewsBreaks – MagneGas Corp. (NASDAQ: MNGA) Reports Improvements in MagneGas2® Production; Shares at New 52-week Low

Shares of MagneGas (NASDAQ: MNGA) are down 4.8% mid-day, trading at a new 52-week low of $0.57. The company this morning reported a 150% improvement in MagneGas2® production rates and a 50% reduction in production costs since the introduction of Butanol as a feedstock in April 2017. “Operationally, the research, development and production of MagneGas2® is one of the largest contributors to our cost structure. The use of butanol positively impacts the Company's financial metrics in several ways. First, we are able to significantly reduce the labor hours required to produce our gas, which enables us to reallocate labor to…

Continue Reading

MondayJul 31, 2017 12:09 pm

NetworkNewsBreaks – InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) Updates on INSPIRE Study; Pulls from New 52-Week Low

Shares of InVivo Therapeutics (NASDAQ: NVIV) are down 27.5% mid-day, lifting off a new 52-week low of $1.70 set this morning. The company earlier today issued an update on the progress of its INSPIRE Study designed to demonstrate the safety and probable benefit of the Neuro-Spinal Scaffold™ for the treatment of complete thoracic spinal cord injury (SCI). InVivo reported overall patient improvements, as well as a temporary enrollment halt due to the death of a patient, unrelated to the company’s treatment. “The most recent patient to enroll into the INSPIRE study, who was implanted in late June 2017, passed away…

Continue Reading

MondayJul 31, 2017 12:04 pm

NetworkNewsBreaks – Mateon Therapeutics, Inc. (MATN) Shares Surge on Positive Initial Data from Phase 1b Study of OXi4503

Shares of Mateon Therapeutics (OTCQX: MATN) are up 26% this morning after the company released preliminary data from its phase 1b dose-ranging study of OXi4503 in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The data show that two of four patients achieved a complete remission after one cycle of treatment. Additionally, there were no dose-limiting toxicities observed in the fifth cohort and OXi4503 continued to have a favorable safety profile. “Every dose of OXi4503 tested in this study has shown encouraging signs of efficacy and a favorable safety profile, with the highest…

Continue Reading

MondayJul 31, 2017 8:56 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Announces Establishment of Hemp Education Center

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced that its wholly-owned subsidiary, ChineseHempOil.com, Inc., has established a Hemp Education Center in San Gabriel, California. Through this club-style education center, the company aims to provide valuable information to those who want to learn more about the potential health benefits of non-industrial hemp and hemp-derived cannabidiol (CBD). “I am delighted about the possibilities of our new Hemp Education Center,” Warren Wang, CEO and founder of CIIX, stated in the news release. “In recognition of the unprecedented opportunities in the legal non-industrial hemp industry, CIIX expanded its business to capitalize on…

Continue Reading

FridayJul 28, 2017 1:09 pm

NetworkNewsBreaks – Windstream Holdings, Inc. (NASDAQ: WIN) Acquires Broadview Networks

Windstream Holdings (NASDAQ: WIN) has completed its acquisition of Broadview Networks Holdings, Inc. The company previously announced the $227.5 million all-cash transaction in April 2017. Additionally, the company announced that Brian Crotty, chief operating officer of Broadview, has been named president of the mid-market and small business division. Various other members of Broadview’s management team have also been added to the small business division. “The addition of Broadview advances our strategy to differentiate ourselves by delivering a truly superior customer experience using disruptive technologies,” Windstream president and chief executive officer Tony Thomas stated in the news release. To view the…

Continue Reading

FridayJul 28, 2017 12:15 pm

NetworkNewsBreaks – Cesca Therapeutics, Inc. (NASDAQ: KOOL) Shares Tick Higher on Issuance of New Cellular Processing Methodology Patent

Cesca Therapeutics (NASDAQ: KOOL) shares are up 7% mid-day on news that SynGen, Inc. (whose cell processing assets were acquired by Cesca’s 80%-owned subsidiary ThermoGenesis Corp.) has been awarded a new patent entitled “Cell Separation Devices, Systems, and Methods” by the U.S. Patent and Trademark Office. The patent covers a device and methodology for integrating automated cellular separation and buoyancy-activated cell sorting processes. “This new patent issuance significantly strengthens the intellectual property position surrounding our proprietary automation technology which is core to our best-in-class ThermoGenesis portfolio of cell processing systems,” Cesca CEO Chris Xu stated in the news release. To…

Continue Reading

FridayJul 28, 2017 9:22 am

NetworkNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Moves Closer to Kimmett Expansion with TSXV Approval of Cannabis Wheaton Investment

Cannabis Wheaton Income Corp. (TSX.V: CBW) this morning announced that it has received approval from the TSX Venture Exchange to purchase $15 million of common shares of ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) at an agreed upon valuation of $2.25 per share. Per the update, this investment forms a portion of a larger phased investment by Cannabis Wheaton aimed at funding the construction of ABcann’s proposed 50,000 square foot addition to its Kimmett cannabis cultivation facility to be located in Napanee, Ontario. This morning’s announcement follows the two companies’ entry into a binding interim agreement on May 29, 2017,…

Continue Reading

ThursdayJul 27, 2017 12:30 pm

NetworkNewsBreaks – Cerus Corp. (NASDAQ: CERS) Partners with Central California Blood Center to Manufacture Pathogen-Reduced Cryoprecipitate

Shares of Cerus (NASDAQ: CERS) are up 15% following news of the company's agreement with the Central California Blood Center (CCBC). CCBC will manufacture for Cerus a pathogen-reduced cryoprecipitate (cryo), a blood product used in the control of bleeding associated with acquired fibrinogen deficiency. “Cryo is a natural extension to our current FDA-approved INTERCEPT Blood System for Plasma. Following approval of a proposed premarket approval (PMA) supplement, INTERCEPT Plasma may be further manufactured into cryoprecipitate, for which we plan to seek an extended 5-day post-thaw storage claim. Given today’s growing emphasis on, and use of, coagulation monitoring and fibrinogen supplementation…

Continue Reading

ThursdayJul 27, 2017 12:27 pm

NetworkNewsBreaks – Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) Says Cigna will Cover ThyGenX® Nationwide

Interpace Diagnostics Group (NASDAQ: IDXG) has entered an agreement with Cigna to provide coverage of the company’s ThyGenX® test, effective immediately. Cigna is one of the largest national health plans in the United States, with 15 million members nationwide. This new agreement brings the number of individuals covered for Interpace’s ThyGenX™ molecular test for indeterminate thyroid nodules to approximately 275 million patients nationwide. “Cigna’s coverage of ThyGenX represents further acceptance among major health plans of our molecular products for Thyroid cancer.  We are pleased that Cigna has joined the growing list of health plans that cover ThyGenX and that their…

Continue Reading